The objective of this study is to evaluate the impact of pharmacogenomic aspects of drug metabolism on the measurement of drug and drug metabolites on urine drug testing (UDT).
Study Type
OBSERVATIONAL
Influence of CYP450 drug metabolism on quantitative UDT
Occurrence of genetically-determined abnormal metabolism of drugs tested with UDT, classified as genetic effects on metabolism (GEM) + for rapid metabolizers, GEM 0 for normal metabolizers, and GEM - for slow metabolizers.
Time frame: 24 months
Occurrence of illicit drugs detected on UDT and the GEM classification associated with these medications
Time frame: 24 months
Non-prescribed drugs detected on UDT and the GEM classification associated with these medications
Time frame: 24 months
False positive immunoassay results, defined as positive immunoassay concurrent with negative quantitative testing
Time frame: 24 months
Frequency of target drug regimen changes by the treating physician due to pharmacogenomic test results
Time frame: 24 months
Frequency of illicit drug changes by the subject due to UDT results, as observed at the time of repeat UDT
Time frame: 24 months
Frequency of non-prescribed drug changes by the subject due to UDT results, as detected at the time of repeat UDT
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.